



Robyn Boerstling

Vice President

Infrastructure, Innovation and Human Resources Policy

March 21, 2017

Lamar Alexander
Chairman
Committee on Health, Education, Labor
and Pensions (HELP)
United States Senate
Washington, DC 20515

Patty Murray
Ranking Member
Committee on Health, Education
and Pensions (HELP)
United States Senate
Washington, DC 20515

Dear Chairman Alexander and Ranking Member Murray:

On behalf of the National Association of Manufacturers (NAM), the largest manufacturing association in the United States representing 14,000 manufacturers in every industrial sector and in all 50 states, I am writing to express strong support for a swift and timely reauthorization of the Food and Drug Administration user fee agreements covering prescription drugs, medical devices, biosimilars and generic drugs.

Manufacturers appreciate the Committee's attention to this issue and today's hearing to discuss advancing legislation that will support America's innovation leadership in the field of life sciences. The Food and Drug Administration's user fee program is the ultimate public-private partnership that supports life-saving medical treatments while advancing science, research and technological innovation.

Manufacturers in the United States drive these breakthroughs and serve as a global leader in a variety of fields, including the pharmaceutical and medical device industries. The recently enacted and NAM-supported 21st Century Cures Act will further modernize our approach to the discovery, development, and delivery of medical innovations. The FDA user fee authorizations (UFAs) are necessary and complementary programs that accelerate new medical breakthroughs. Any delay of these reauthorizations risks future gains in medical discovery and harm to our global standing.

The United States leads the world in the introduction of new medicines, treatments and medical innovation. Manufacturers support research pipelines that will lead to further advancement in the development of treatments and products as well as the creation of more jobs that support innovation and scientific advancement. Today's hearing is an important step and manufacturers urge the Senate HELP Committee to maintain the momentum initiated by your leadership.

Sincerely,

A handwritten signature in blue ink that reads 'Robyn M. Boerstling'.

Robyn M. Boerstling

Leading Innovation. Creating Opportunity. Pursuing Progress.